biokine_amir

About Amir Caspi

This author has not yet filled in any details.
So far Amir Caspi has created 55 blog entries.

BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications

Transaction increases BioLineRx’s stake by 20%, to 80%, ahead of numerous potential value-creating milestones. Top-line results from ongoing Phase 2a pancreatic cancer study in combination with KEYTRUDA® expected this quarter.

October 3rd, 2018|Clinical Program BL8040, Recent News|

BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization

Data from first lead-in patient cohort prompts Data Monitoring Committee to recommend early continuation to randomized placebo-controlled part 2 of trial.

August 7th, 2018|Clinical Program BL8040, Recent News|

BioLineRx Announces Expansion of Immuno-Oncology Collaboration in Pancreatic Cancer

x30-50 patients in additional arm will be investigated under the collaboration. Results from combination of BL-8040 and KEYTRUDA® (pembrolizumab) in COMBAT/KEYNOTE-202 study will be reported in H2 2018 as planned.

July 30th, 2018|Clinical Program BL8040, Recent News|

BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization for Allogeneic Bone Marrow Transplantation

BL-8040 was safe and well tolerated, and all transplanted recipients were successfully engrafted

May 17th, 2018|Clinical Program BL8040, Recent News|

BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid Leukemia

Patent valid through March 2034, with up to five years’ patent term extension

May 16th, 2018|Clinical Program BL8040|

BioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival by Mediating Tumor Infiltration of Antigen-Specific T-cells

January 23rd, 2018|Clinical Program BL8040|

BioLineRx Announces Initiation of Phase 3 GENESIS Trial in Stem-Cell Mobilization for Autologous Transplantation in Multiple Myeloma Patients

Study will assess mobilization of hematopoietic stem cells by BL-8040 compared to placebo, on top of G-CSF, for autologous transplantation in multiple myeloma patients

December 21st, 2017|Clinical Program BL8040|

BioLineRx Reports Overall Survival Results from Long-Term Follow-Up of Phase 2a Trial in r/r AML

BL-8040 in combination with high-dose Ara-C significantly improved overall survival compared to historical data

December 4th, 2017|Clinical Program BL8040|

BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer under Immunotherapy Collaboration

Combination trial of BL-8040 and atezolizumab are part of initiative for the development of novel cancer immunotherapy combinations

July 10th, 2017|Clinical Program BL8040|

BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination with Atezolizumab for Solid Tumors

Genentech has submitted all three solid tumor trials planned under its cancer immunotherapy collaboration with BioLineRx. Studies will investigate the combination in pancreatic cancer, gastric cancer and non-small cell lung cancer (NSCLC)

June 1st, 2017|Clinical Program BL8040|